MariTide: Side Effects

Safety Overview#

MariTide's safety profile has been characterized in Phase 1 (Nature Metabolism) and Phase 2 (NEJM, 592 participants) trials. The adverse event profile is consistent with the GLP-1 receptor agonist class, with GI events being the most common. No new safety signals were identified in Phase 2, and tolerability was consistent with GLP-1 class medications.

Gastrointestinal Adverse Events#

GI events were the most common adverse events:

• Most GI adverse events were mild to moderate
• Consistent with the GLP-1 receptor agonist class
• No new safety signals identified beyond expected GLP-1 class effects
• Monthly dosing interval did not appear to worsen tolerability

Comparison with Weekly GLP-1 Agonists#

MariTide's monthly dosing and antibody-peptide format may produce a different GI tolerability profile compared to weekly peptide-based therapies. The sustained, steady-state drug levels from the ~21-day half-life may reduce peak-related GI effects compared to weekly bolus dosing. However, formal comparisons are not available.

Treatment Discontinuation#

Discontinuation rates due to adverse events in Phase 2 were not separately disclosed in detail but were characterized as tolerable. Full discontinuation data will be available in the Phase 3 MARITIME program.

GLP-1 Agonist Class Warnings#

As a GLP-1 receptor agonist, MariTide is expected to carry standard class warnings:

Thyroid C-Cell Tumors#

GLP-1 receptor agonists carry a class-wide warning for thyroid C-cell tumors in rodent studies. MariTide would be expected to carry similar warnings.

Pancreatitis#

GLP-1 agonists have been associated with pancreatitis. Patients should report persistent severe abdominal pain.

Gallbladder Disease#

Significant weight loss (~20% at 52 weeks) increases the risk of cholelithiasis.

Acute Kidney Injury#

GI-related dehydration may contribute to AKI risk.

Antibody-Specific Considerations#

Immunogenicity#

As an antibody-based therapeutic, MariTide may elicit anti-drug antibodies (ADAs). Immunogenicity data from the Phase 2 trial have not been fully disclosed. The development of ADAs could potentially affect efficacy or safety over long-term use.

Injection Site Reactions#

Antibody-based therapeutics may have different injection site reaction profiles compared to peptide-only drugs due to the larger molecule size and potential for local immune reactions.

Long Half-Life Considerations#

The ~21-day half-life means that adverse effects, once present, may persist longer than with weekly or daily therapies. Conversely, it also means drug effects persist longer between doses, which is beneficial for adherence.

Heart Rate Effects#

GLP-1 agonists typically increase resting heart rate by 2-4 bpm. Heart rate effects specific to MariTide have not been separately characterized.

Special Populations#

Full data on safety in renal impairment, hepatic impairment, elderly, and pediatric populations are not yet available from early-phase trials.

Drug Interactions#

• Insulin and sulfonylureas: Dose reduction may be needed
• Oral medications: GLP-1 agonism delays gastric emptying
• Oral contraceptives: Consider alternative contraception

Safety Profile Context#

MariTide belongs to the Metabolic category of research peptides. Understanding the side effect profile of MariTide is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of MariTide. Side effect severity and frequency are based on available clinical data.

Nausea#

Severity: mild | Frequency: very-common

Most common GI adverse event. Consistent with GLP-1 receptor agonist class. Generally mild to moderate and tends to improve with continued treatment.

Vomiting#

Severity: mild | Frequency: common

Common GI adverse event. Generally mild to moderate and transient.

Diarrhea#

Severity: mild | Frequency: common

Commonly reported GI adverse event. Usually mild to moderate and self-limiting.

Constipation#

Severity: mild | Frequency: common

Related to GLP-1 receptor agonist-mediated gastric emptying delay.

Injection site reactions#

Severity: mild | Frequency: common

Reported with the subcutaneous antibody-peptide injection. Generally mild. Antibody-based therapeutics may have different injection site profiles than peptide-only drugs.

Contraindications#

The following contraindications have been identified for MariTide based on available research and pharmacological considerations:

• MariTide is investigational and not approved for any indication. Use only within clinical trials.
• Expected GLP-1 agonist class contraindication: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy (GLP-1 agonist class)
• Prior serious hypersensitivity to MariTide or excipients

Individuals with any of these conditions should not use MariTide without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for MariTide:

• Insulin and sulfonylureas: Increased risk of hypoglycemia when combined (GLP-1 agonist class interaction)
• Oral medications: GLP-1 receptor agonists may delay gastric emptying and affect absorption of co-administered oral drugs
• Oral contraceptives: Gastric emptying delay may reduce absorption; consider non-oral contraception during initiation

Drug interaction studies for MariTide remain limited. Researchers should exercise caution when combining MariTide with other compounds and consult relevant pharmacological references.

Related Reading#

• MariTide overview and research guide
• MariTide dosing protocols
• MariTide risks and legal status